This article will continue the discussion held by a group of attorneys during a recent Pradaxa litigation seminar. The discussion centered primarily around venue although cause of action and filing were also discussed. Boehringer’s primary American base is in Connecticut which is also the home of large numbers of insurance companies. This can lead to extremely tough jury pools and is something to consider when discussing alternative venues.

Continuing from Part One of the Pradaxa Lawsuit articles, we continue with the discussion held by attorneys who are interested in Pradaxa litigation and the issues they found to be of primary importance. Discussed at length was the RE-LY study Boehringer Ingelheim used in order to receive FDA approval

A group of attorneys interested in the Pradaxa litigation assembled to discuss the issue in a recent seminar. Pradaxa is a drug prescribed primarily for atrial fibrillation, which is essentially an irregular heartbeat.

As a continuing discussion of the science behind the medication Pradaxa, used in the treatment of atrial fibrillation, it is believed that the high incidence GI issues experienced in Pradaxa users relates directly to its unique delivery system. Pradaxa is absorbed most readily when low pH levels are present.

Pradaxa is a prescription drug manufactured by Boehringer Ingelheim which is most commonly prescribed for symptoms of atrial fibrillation. Atrial fibrillation is a condition in which the two upper chambers of the heart slowly begin to fail to rhythmically contract. These chambers then flutter in an irregular manner, which, in some cases, has little effect on the overall health of the patient other than a modest reduction in cardiac output.

Pradaxa is a drug which is a newcomer into the pharmaceutical marketplace, used in the treatment of atrial fibrillation and the subsequent prevention of strokes. The only drug of its kind, Warfarin, has been in use as an anticoagulant and to treat atrial fibrillation for over half a century—since 1957

Approved by the FDA in October 2010, Pradaxa is the first anticoagulant drug to be marketed in over half a century. Warfarin was approved for use in 1957 and despite its limitations has been used ever since. Both drugs are used in the treatment of atrial fibrillation which can lead to stroke.

Boehringer Ingelheim announced in March of 2008 that the European Commission had granted approval to market their new oral thrombin inhibitor known as Pradaxa 27 EU states. At this juncture it was expected that Pradaxa would soon be released in Germany and the UK as well.

If your doctor has prescribed the relatively new drug, Pradaxa, as an alternative to Warfarin, you may have been alarmed to hear of the potential issues with Pradaxa. Pradaxa was approved by the FDA in late 2010 after the manufacturer, Boehringer Ingelheim, presented the drug as a much better alternative to Warfarin.

Pradaxa, the drug which less than a couple of years ago seemed like a dream come true for the hundreds of thousands of patients who were taking Warfarin or Coumadin has had its initial glow tarnished by the ever-increasing number of reports of serious side effects from use of the drug. Although Warfarin has been used as a stroke inhibitor and for those suffering from atrial fibrillation since the 1950’s, it comes with certain restrictions and its own set of side effects.